Alector (ALEC) Expected to Release Earnings on Thursday

Alector (NASDAQ:ALEC) will likely be posting its Q2 2026 results after the market closes on Thursday, August 6th. Analysts expect Alector to announce earnings of ($0.2213) per share and revenue of $1.4280 million for the quarter. Parties can check the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Thursday, August 13, 2026 at 4:30 PM ET.

Alector (NASDAQ:ALEC) last released its quarterly earnings results on Thursday, May 7th. The company reported ($0.21) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.29) by $0.08. The firm had revenue of $1.05 million for the quarter, compared to the consensus estimate of $9.67 million. Alector had a negative net margin of 680.83% and a negative return on equity of 295.17%. On average, analysts expect Alector to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Alector Stock Up 1.7%

NASDAQ:ALEC traded up $0.03 on Tuesday, reaching $1.53. The stock had a trading volume of 50,283 shares, compared to its average volume of 767,081. The company has a current ratio of 5.25, a quick ratio of 5.25 and a debt-to-equity ratio of 0.80. The company has a 50-day moving average of $1.72 and a 200 day moving average of $2.01. The stock has a market cap of $170.43 million, a P/E ratio of -1.29 and a beta of 0.60. Alector has a 12-month low of $1.09 and a 12-month high of $3.40.

Insider Buying and Selling

In other news, CEO Arnon Rosenthal sold 87,216 shares of the business’s stock in a transaction on Tuesday, June 2nd. The shares were sold at an average price of $1.97, for a total transaction of $171,815.52. Following the completion of the transaction, the chief executive officer owned 2,367,206 shares of the company’s stock, valued at approximately $4,663,395.82. The trade was a 3.55% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CFO Neil Lindsay Berkley sold 19,360 shares of the business’s stock in a transaction dated Tuesday, June 2nd. The shares were sold at an average price of $1.97, for a total transaction of $38,139.20. Following the transaction, the chief financial officer directly owned 379,900 shares of the company’s stock, valued at $748,403. The trade was a 4.85% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 115,760 shares of company stock valued at $227,734 in the last 90 days. Insiders own 8.30% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of ALEC. Virtu Financial LLC acquired a new stake in shares of Alector in the 4th quarter worth approximately $34,000. Invesco Ltd. grew its position in Alector by 45.3% in the fourth quarter. Invesco Ltd. now owns 279,468 shares of the company’s stock worth $436,000 after buying an additional 87,157 shares during the last quarter. Mackenzie Financial Corp boosted its stake in shares of Alector by 132.7% during the 4th quarter. Mackenzie Financial Corp now owns 660,168 shares of the company’s stock worth $1,001,000 after acquiring an additional 376,456 shares in the last quarter. XTX Topco Ltd grew its holdings in shares of Alector by 501.8% in the 4th quarter. XTX Topco Ltd now owns 592,839 shares of the company’s stock worth $925,000 after acquiring an additional 494,326 shares during the last quarter. Finally, Ikarian Capital LLC raised its position in shares of Alector by 174.0% during the fourth quarter. Ikarian Capital LLC now owns 2,082,606 shares of the company’s stock worth $3,249,000 after purchasing an additional 1,322,606 shares during the period. Institutional investors own 85.83% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms recently commented on ALEC. Weiss Ratings reiterated a “sell (e+)” rating on shares of Alector in a research note on Friday. Wall Street Zen raised Alector from a “sell” rating to a “hold” rating in a research report on Saturday, May 9th. Cantor Fitzgerald upgraded Alector from a “neutral” rating to an “overweight” rating in a research note on Wednesday, April 15th. Finally, Morgan Stanley reissued an “underweight” rating and set a $2.00 price objective on shares of Alector in a report on Monday, May 4th. Three research analysts have rated the stock with a Buy rating, three have given a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $3.62.

About Alector

Alector is a clinical-stage biotechnology company headquartered in South San Francisco, California. Founded in 2013, the company is focused on discovering and developing immuno-neurology therapies that target the innate immune system to treat a range of neurodegenerative disorders. Alector’s approach aims to harness the body’s natural defense mechanisms to clear pathological proteins and restore neuronal function in conditions such as Alzheimer’s disease and frontotemporal dementia.

The company’s pipeline includes multiple product candidates in both preclinical and clinical stages, with lead programs AL001 and AL002 advancing in frontotemporal dementia and Alzheimer’s disease studies.